Efficacy of Lenabasum in Patients With Dermatomyositis and Refractory Skin Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Investigative Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin Disease A Randomized Clinical Trial
J Invest Dermatol 2022 Apr 28;[EPub Ahead of Print], VP Werth, E Hejazi, SM Pena, J Haber, M Zeidi, N Reddy, J Okawa, R Feng, MM Bashir, K Gebre, AS Jadoo, JSS Concha, N Dgetluck, S Constantine, B WhiteFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.